Add time:08/18/2019         Source:sciencedirect.com

A series of new pyrazolo[3,4-b]pyridin-3-yl pyrimidine derivatives were synthesized and evaluated for the activation of sGC. Compared with riociguat, compound 13a exhibited equivalent in vitro activity on preconstricted rat thoracic aorta rings and in Rat heart Langendorff preparation. Compound 13a also showed acceptable PK profiles, which might become a promising candidate for the treatment of pulmonary hypertension.

We also recommend Trading Suppliers and Manufacturers of 3-BROMO-1-METHYL-1H-PYRAZOLO[3,4-B]PYRIDINE (cas 116855-03-9). Pls Click Website Link as below: cas 116855-03-9 suppliers